Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

12.32

Margin Of Safety %

Put/Call OI Ratio

0.22

EPS Next Q Diff

-0.14

EPS Last/This Y

-0.36

EPS This/Next Y

0.81

Price

37.3

Target Price

78.95

Analyst Recom

1.32

Performance Q

-23.65

Relative Volume

1.85

Beta

0.81

Ticker: CYTK



22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-06CYTK43.240.210.1266385
2025-03-07CYTK43.480.210.0466600
2025-03-10CYTK43.320.210.0666680
2025-03-11CYTK44.180.210.0967498
2025-03-12CYTK44.190.210.0268104
2025-03-13CYTK44.420.210.0568697
2025-03-14CYTK44.340.210.0369764
2025-03-17CYTK44.880.200.0470515
2025-03-18CYTK43.260.200.1270752
2025-03-19CYTK43.430.200.0171416
2025-03-20CYTK43.140.200.4972941
2025-03-21CYTK45.450.210.0774661
2025-03-24CYTK46.540.190.1867050
2025-03-25CYTK44.750.200.3568101
2025-03-26CYTK43.640.200.0269605
2025-03-27CYTK42.970.210.5769504
2025-03-28CYTK43.220.210.0569667
2025-03-31CYTK40.180.210.1569977
2025-04-01CYTK37.830.210.4671129
2025-04-02CYTK40.20.210.3471310
2025-04-03CYTK40.540.220.3172296
2025-04-04CYTK37.370.220.2873134
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1



22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-06CYTK43.28-2.4-134.0-5.57
2025-03-07CYTK43.46-2.4-146.9-5.60
2025-03-10CYTK43.35-2.4-142.1-5.60
2025-03-11CYTK44.48-2.4-161.5-5.60
2025-03-12CYTK43.96-2.4-136.8-5.60
2025-03-13CYTK44.43-2.4-150.2-5.60
2025-03-14CYTK44.36-2.4-142.8-5.60
2025-03-17CYTK44.91-2.4-151.8-5.60
2025-03-18CYTK43.24-2.4-117.9-5.60
2025-03-19CYTK43.45-2.4-146.0-5.60
2025-03-20CYTK43.10-2.3-177.6-5.64
2025-03-21CYTK45.47-2.3-223.5-5.64
2025-03-24CYTK46.57-2.3-202.1-5.64
2025-03-25CYTK44.55-2.3-152.1-5.64
2025-03-26CYTK43.63-2.3-168.5-5.64
2025-03-27CYTK42.95-2.3-172.2-5.64
2025-03-28CYTK43.19-2.3-186.9-5.64
2025-03-31CYTK40.18-2.4-132.8-5.62
2025-04-01CYTK37.50-2.4-134.5-5.62
2025-04-02CYTK40.25-2.4-237.3-5.62
2025-04-03CYTK40.58-2.4-189.5-5.62
2025-04-04CYTK37.30-2.4-125.5-5.62
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1



22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-06CYTK-4.43-4.0813.06
2025-03-07CYTK-4.43-4.0813.06
2025-03-10CYTK-5.13-4.0713.06
2025-03-11CYTK-5.13-4.0713.06
2025-03-12CYTK-5.19-4.0712.19
2025-03-13CYTK-5.98-4.0712.19
2025-03-14CYTK-6.03-4.0712.19
2025-03-17CYTK-7.01-4.1212.19
2025-03-18CYTK-7.64-4.1212.19
2025-03-19CYTK-7.70-4.1212.19
2025-03-20CYTK-7.70-4.1212.19
2025-03-21CYTK-7.70-4.1212.19
2025-03-24CYTK-7.70-4.1112.19
2025-03-25CYTK-7.64-4.1112.19
2025-03-26CYTK-7.64-4.1112.32
2025-03-27CYTK-7.64-4.1112.32
2025-03-28CYTK-7.64-4.1112.32
2025-03-31CYTK-8.07-4.1112.32
2025-04-01CYTK-7.93-4.1112.32
2025-04-02CYTK-7.72-4.1112.32
2025-04-03CYTK-7.72-4.1112.32
2025-04-04CYTK-7.73-4.1112.32
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS​

-1.26

Avg. EPS Est. Current Quarter

-1.36

Avg. EPS Est. Next Quarter

-1.4

Insider Transactions

-7.73

Institutional Transactions

-4.11

Beta

0.81

Average Sales Estimate Current Quarter

2

Average Sales Estimate Next Quarter

2

Fair Value

Quality Score

10

Growth Score

43

Sentiment Score

5

Actual DrawDown %

66.2

Max Drawdown 5-Year %

-65.3

Target Price

78.95

P/E

Forward P/E

PEG

P/S

239.51

P/B

P/Free Cash Flow

EPS

-5.28

Average EPS Est. Cur. Y​

-5.62

EPS Next Y. (Est.)

-4.81

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3191.11

Relative Volume

1.85

Return on Equity vs Sector %

415.7

Return on Equity vs Industry %

428.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

-125.5
Cytokinetics, Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 498
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today
news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance
stock history CYTK – Cytokinetics, Incorporated invest stock market
stock prices CYTK premarket after hours
ticker CYTK fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About